December 19, 2025
1 min read

FDA outlined concerns with Elevidys’ manufacturing at Catalent site, Form 483 shows

The Elevidys-related manufacturing shortfalls were described in one of two Form 483s tied to FDA inspections that came before Catalent’s layoff spree at its Maryland gene therapy manufacturing business.

Leave a Reply

Your email address will not be published.

Previous Story

Different Mental Health Conditions Share Similar Genetics, Study Says

Next Story

Nestlé expands Materna supplement line to support pregnancy and postpartum health

Previous Story

Different Mental Health Conditions Share Similar Genetics, Study Says

Next Story

Nestlé expands Materna supplement line to support pregnancy and postpartum health

Latest from Blog

NEWS CENTER Maine

Through in-depth storytelling, through direct contact on digital on social platforms, through long-standing community service programs like Coats & Toys for Kids, Project Heat and Buddy to Buddy, NEWS CENTER Maine is
Go toTop